Stocks to Watch: Elan, Theravance, Take-Two

NEW YORK -- Elan ( ELN) and Theravance ( THRX) reached a $1 billion agreement in which Elan will buy 21% of royalties that Theravance receives from GlaxoSmithKline ( GSK) for four respiratory drugs.

The deal includes Breo Ellipta, a new treatment for chronic obstructive pulmonary disease that received approval from the Food and Drug Administration last week.

4 Stocks Spiking on Big Volume


Take-Two Interactive Software ( TTWO) is expected by analysts on Monday to post fiscal fourth-quarter earnings of 23 cents a share on revenue of $280.1 million.


Cereal company Post Holdings ( POST) is expected by Wall Street to report fiscal second-quarter earnings of 27 cents a share on revenue of $255.7 million.


Ann Inc. ( ANN) is forecast to post first-quarter earnings of 43 cents a share on sales of $582 million.


Pacific Sunwear ( PSUN) is expected by analysts on Monday to post a first-quarter loss of 19 cents a share.

5 Stocks Poised to Break Out


-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

If you liked this article you might like

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

Despite Shkreli Drama, Retrophin Looks Interesting Now

Despite Shkreli Drama, Retrophin Looks Interesting Now

Celtic Tiger Tries to Roar Again

Celtic Tiger Tries to Roar Again

Cramer's 6 Stocks in 60 Seconds: PRGO CREE HOG GME ORCL MHK (Update 1)

Cramer's 6 Stocks in 60 Seconds: PRGO CREE HOG GME ORCL MHK (Update 1)